Review
Open access
Sep 2026
Long-Term Survival Heterogeneity Across PD-L1-Defined Subgroups in Pembrolizumab-Treated Non-Small-Cell Lung Cancer: A Model-Based Analysis
Background/Objectives: Immune checkpoint inhibitors have substantially improved survival outcomes in non-small-cell lung cancer (NSCLC). However, survival heterogeneity across PD-L1-defined and other clinically relevant patient subgroups remains incompletely characterized, limiting subgroup-specific interpretation of p...
Heungjo Kim, Sungjae Lee, Hongjae Lee et al.
· Pharmaceutics · 0 citations